NEWSROOM

124 results have been found

Corporate
Investors
Products

2019
2018
2017
2016
2015

Order by: Newest A-Z

July 4, 2019

Grifols announces FDA approval of Xembify^®, 20% subcutaneous immunoglobulin for primary immunodeficiencies

July 3, 2019

Grifols selected to build its first intravenous solutions manufacturing line in Africa

June 27, 2019

Grifols discloses transfers of value made to European healthcare professionals and health-sector organizations in 2018

June 19, 2019

Grifols to launch plasma-protein-based bleeding-control solutions

May 24, 2019

Grifols reinforces its long-term and sustainable growth strategy with EUR 1,400 million in capital investments in 2018-2022

Content: footer-organization-info

The information contained on the Grifols worldwide website is not applicable to all countries. For specific information on the products and services available in your country, please select your country from the list included in the corresponding section. The purpose of this website is to provide information about Grifols' products and services, and it is not intended for, nor may it be construed to, promoting any products in countries in which they are not approved.